TENAX THERAPEUTICS, INC. 8K

Tenax Therapeutics reported Q2 2026 results, extended its cash runway to mid-2028, and confirmed expectations for August 2026 topline data and late-August ESC presentation from its Phase 3 LEVEL trial of TNX-103 for PH-HFpEF, while progressing enrollment in the LEVEL-2 Phase 3 trial.

On July 31, 2026, Tenax Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a corporate update, highlighting a cash and cash equivalents balance of $118.0 million (extended via $13.4 million in warrant exercise proceeds to fund operations through the second quarter of 2028), increased R&D expenses tied to its Phase 3 LEVEL and LEVEL-2 trials, and a quarterly net loss of $17.8 million; the company reiterated that it expects to report topline data from its Phase 3 LEVEL trial of TNX-103 for PH-HFpEF in August 2026, with results planned for presentation at the ESC Congress 2026 in late August in Munich, and noted that enrollment in its second global pivotal trial LEVEL-2, initiated in December 2025, is expected to be completed by the end of 2027.

Filing Facts

CIK

34956

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-326784

Alert Tier

6